Real-world data on the effectiveness and safety of upadacitinib in the treatment of moderate-severe atopic dermatitis are limited.

This interim analysis investigated effectiveness and safety of upadacitinib 15 mg or 30 mg daily in a large atopic dermatitis real-world population throughout 48 weeks of observation.

A significant improvement in the clinical signs and symptoms of atopic dermatitis was detected in the overall population by Week 16 and throughout the study period.

The percentage of patients treated with either 15 or 30 mg upadacitinib daily and achieving EASI 75, EASI 90 and EASI 100 responses was: 78.2%, 47.6% and 28.2% of patients at 16 weeks and 87.6%, 69.1% and 44.3% at Week 48.